Compare Merck & Co., Inc. (MRK) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Virgin Galactic Holdings, Inc. — how do they compare? Merck & Co., Inc. trades at $125.97 (market cap $307.25B), while Virgin Galactic Holdings, Inc. trades at $2.78 (market cap $329.06M). The key difference: Merck & Co., Inc. is far larger — about 933.7× Virgin Galactic Holdings, Inc.'s market cap, and Merck & Co., Inc. pays a 2.73% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals.
| MRK | SPCE | |
|---|---|---|
Market Cap | $307.25B | $329.06M |
Sector | Health | Industrials |
52-Week High | $129.52 | $7.52 |
52-Week Low | $77.60 | $2.17 |
Enterprise Value | $350.66B | $428.90M |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
SPCE trades at $2.78, up 8.59% in the last session, but remains in a bearish technical trend with negative cash flows and deep losses. The company reported a net loss of $278.91 million on minimal revenue of $1.54 million in 2025, with profitability metrics deeply negative. Recent news highlights volatility tied to space sector sentiment and SpaceX's market activities, contributing to sharp price swings.
The outlook is highly speculative with significant execution and funding risks. While analyst ratings are mixed, the lack of revenue scale and persistent cash burn pose substantial challenges. Investment potential hinges on successful commercialization, but current fundamentals do not support a sustainable valuation, making it suitable only for high-risk investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
